Michael Schmertzler, Director at PTC THERAPEUTICS, INC. (PTCT), sold 20,000 shares at $66.58 ($1.3M) on 2026-09-16, disclosed to the SEC on 2026-09-18.
Scheduled sale ($1.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.58 | 2,994 | $199K | 14.8% |
| 2 | $67.35 | 7,006 | $472K | 35.0% |
| 3 | $67.83 | 9,624 | $653K | 48.4% |
| 4 | $68.45 | 376 | $26K | 1.9% |
| Total | $67.49 avg | 20,000 | $1.3M | 100% |
| Filing → |
| PTCT | SELL | 2026-08-21 | $1.8M | — | Filing → |
| PTCT | SELL | 2024-01-10 | $42K | — | Filing → |
| PTCT | SELL | 2023-06-09 | $45K | — | Filing → |